Systematic review of parenteral ketamine for managing acute agitation in emergency settings.
Christopher Peter, Satish Suhas, Guru S Gowda, Deepak Ghadigaonkar, Krishna Prasad Muliyala, Venkata Senthil Kumar Reddi
Asian journal of psychiatry January 1, 2025 DOI: 10.1016/j.ajp.2024.104344 via PubMed
Summary
AI-generated from the abstractAcute agitation occurs in 2.6% of emergency cases and up to 12.2% among patients with schizophrenia or bipolar disorder. Ketamine, given by injection, provides rapid sedation, with an average onset of 6.1 minutes. In a systematic review of 29 studies involving 1516 patients (mean age 35.5, 67.9% male), most received intramuscular ketamine at a mean dose of 3.83 mg/kg. However, 24.5% needed additional doses or rescue medications. Adverse effects included tachycardia (5.1%), hypertension (5.5%), hypersalivation (5.6%), and rare cardiac arrest (0.2%). Intubation occurred in 19.1%, but this could not be attributed solely to ketamine. No evidence showed worsening of psychotic symptoms.
Study at a glance
| Characteristics | Systematic review Peer reviewed |
|---|---|
| Sample size | 1,516 |
| Population | Patients receiving parenteral ketamine for acute agitation in emergency settings |
| Intervention | ketamine |
| Dose | mean dose of 3.83 ± 1.07 mg/kg intramuscularly, 2.09 ± 1.56 mg/kg intravenously |
| Topics | Ketamine |
| Keywords | Aggression Psychiatry Emergency medicine Psychiatric emergencies Sedation |
| Citations | 6 |
| Key finding | Parenteral ketamine provides rapid sedation for acute agitation, with an average onset of 6.1 minutes, but 24.5% of patients required additional doses or rescue medications. |
Abstract
Agitation, a significant psychiatric issue often linked to conditions like schizophrenia, bipolar disorder, and major depression, invariably pose challenges in emergency settings. Acute agitation occurs in 2.6 % of emergency cases and up to 12.2 % among patients with schizophrenia or bipolar disorder. With limited available options for effective management of acute agitation, ketamine is emerging as a fast-onset alternative to antipsychotics like haloperidol. This systematic review, following PRISMA guidelines, searched databases in April 2024 for studies on parenteral ketamine for acute agitation in emergency settings. Data extraction included patient demographics, ketamine administration details, sedation time, need for additional doses, adverse events, and intubation rates. The search yielded 7410 results, narrowing to 29 suitable studies with 1516 patients (mean age 35.5 ± 12.4 years, 67.9 % male). Ketamine was administered intramuscularly (IM) in 69 % of studies, intravenously (IV) in 6.9 %, and either IV or IM in 24.1 %. Most patients (86.5 %) received IM ketamine at a mean dose of 3.83 ± 1.07 mg/kg, while 13.5 % received IV ketamine at 2.09 ± 1.56 mg/kg. Sedation occurred on average in 6.1 min. However, 24.5 % needed rescue medications or additional doses. Adverse effects included tachycardia (5.1 %), hypertension (5.5 %), hypersalivation (5.6 %), nausea (2.1 %), emergence reactions (1.4 %), and, rarely, cardiac arrest (0.2). While 19.1 % required intubation, the reasons for the same could not be attributed to ketamine exclusively. Furthermore, there was no evidence for worsening or development of psychotic symptoms with ketamine. This review highlights the effectiveness and safety of parenteral ketamine for managing acute agitation in emergency settings. However, further research is needed to optimize ketamine use in this challenging scenario.